Altre lingue IR-Med Inc.

Azioni

IRME

US46265R1032

Tempo differito OTC Markets Altri mercati azionari 21:49:55 16/05/2024			Variaz. 5gg	Var. 1 gen.
0,6412 ^USD	-24,56%		-28,74%	-44,23%

05/04	PressureSafe di IR-Med Inc. riceve l'elenco FDA per l'indicazione di dispositivo di supporto decisionale per le lesioni da pressione	CI
01/04	IR-Med Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	05/04
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	05/04
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer	05/03
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer	28/02
IR-Med Inc. Announces Resignation of Inna Martin as Director	23/02
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries	20/02
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16	13/02
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16	13/02
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine	21/12
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue	07/12
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer	04/10/23
IR-MED Announces Executive Changes Effective as of October 15, 2023	04/10/23
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024	26/09/23
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024	26/09/23
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board	13/09/23
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board	13/09/23
IR-MED Chairman & Interim CEO Issues Letter to Shareholders	21/08/23
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue IR-Med Inc.

Azioni

IRME

US46265R1032

Altre lingue

Filtri